Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFPT1 | Q06210 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | VNN1 | O95497 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | APAF1 | O14727 | 1/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5744909 | 0.92 | GFPT1 (0.46) | GFPT1CYP1A2PDE10AMAPK13MAPK12 | |
| SCHEMBL5744347 | 0.92 | VNN1 (0.49) | GFPT1CYP1A2MAPK13MAPK12MAPK11 | |
| SCHEMBL5743070 | 0.92 | VNN1 (0.49) | GFPT1CYP1A2MAPK13MAPK12MAPK11 | |
| SCHEMBL5744619 | 0.91 | GFPT1 (0.49) | GFPT1PDE10AAPAF1NSD2CASP3 | |
| SCHEMBL5744593 | 0.91 | GFPT1 (0.60) | GFPT1CYP1A2PDE10AMAPK13MAPK12 | |
| SCHEMBL5744740 | 0.91 | GFPT1 (0.45) | GFPT1CYP1A2PDE10AMAPK13MAPK12 | |
| SCHEMBL5742428 | 0.91 | GFPT1 (0.45) | GFPT1CYP1A2PDE10AMAPK13MAPK12 | |
| SCHEMBL5745176 | 0.91 | GFPT1 (0.45) | GFPT1CYP1A2PDE10AMAPK13MAPK12 | |
| SCHEMBL5746001 | 0.90 | GFPT1 (0.52) | GFPT1CYP1A2PDE10AMAPK13MAPK12 | |
| SCHEMBL5745432 | 0.90 | LMNA (0.48) | GFPT1CYP1A2PDE10AVNN1APAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067529-B2 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2006-06-27 | — | — | US | claimed |
| EP-1631551-A2 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-08 | — | — | EP | claimed |
| US-20040259910-A1 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | BOLIN DAVID ROBERT (US) | 2004-12-23 | — | — | US | claimed |
| WO-2004101528-A2 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | WO | claimed |
| CN-100540537-C | GFAT inhibitors | HOFFMANN LA ROCHE (CH) | 2009-09-16 | — | — | CN | disclosed |
| US-7067529-B2 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2006-06-27 | — | — | US | disclosed |
| CN-1791581-A | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | HOFFMANN LA ROCHE (CH) | 2006-06-21 | — | — | CN | disclosed |
| EP-1631551-A2 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-08 | — | — | EP | disclosed |
| US-20040259910-A1 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | BOLIN DAVID ROBERT (US) | 2004-12-23 | — | — | US | disclosed |
| WO-2004101528-A2 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259910-A1 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | GFPT1, GLS2, GLS | GFPT1 1/4885CYP1A2 1251/4885PDE10A 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.